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Abstract The costs and efforts for sample preparation of
hundreds of individuals, their genomic enrichment for
regions of interest, and sufficient deep sequencing bring a
significant burden to next-generation sequencing-based
experiments. We investigated whether pooling of samples
at the level of genomic DNA would be a more versatile
strategy for lowering the costs and efforts for common
disease-associated rare variant detection in candidate genes
or associated loci in a substantial patient cohort. We
performed a pilot experiment using five pools of 20
abdominal aortic aneurysm (AAA) patients that were
enriched on separate microarrays for the reported 9p21.3
associated locus and 42 additional AAA candidate genes,
and sequenced on the SOLiD platform. Here, we discuss
challenges and limitations connected to this approach and
show that the high number of novel variants detected per
pool and allele frequency deviations to the usually highly
false positive cut-off region for variant detection in non-
pooled samples can be limiting factors for successful
variant prioritization and confirmation. We conclude that
barcode indexing of individual samples before pooling
followed by a multiplexed enrichment strategy should be
preferred for detection of rare genetic variants in larger
sample sets rather than a genomic DNA pooling strategy.
Keywords Abdominal aortic aneurysm.Common disease.
Rare variants.Targeted genomic enrichment.Genomic
DNA pooling.SOLiD next-generation sequencing
Introduction
Abdominal aortic aneurysm (AAA) is classified as an
increase in the aortic diameter of ≥50% or an infrarenal
diameter of ≥30 mm and can be asymptomatic until a
rupture event with a high chance of mortality occurs [1].
The main risk factors include advanced age, male gender,
smoking, other cardiovascular disease, and positive family
history [2–4]. AAA is therefore considered a multi-factorial
disorder in which both environmental and genetic factors
are believed to contribute to its pathogenesis [5]. In spite of
a number of familial [6–9] and population studies [10–15],
the major part of the heritability of AAA formation in
general is not explained and a better understanding of
genetic variants contributing to this phenotype is required.
Although the impact of common–higher allele frequency
variants was shown to be significant [16], genetic models of
common diseases changed with recent discoveries and
possibilities of next-generation sequencing (NGS). The
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variant hypothesis but now tends more to common disease/
rare variant hypothesis [17, 18]. Common diseases can be
explained by a so-called “pathway model” (Fig. 1). This
model assumes that disease of a specific organ or tissue can
be caused by impairment of any pathway influencing the
physiological function of the organ or tissue. Each pathway
contains several genes and rare variants in relevant genes
can contribute to the onset of the disease.
Targeted genomic enrichment approaches with NGS
enable deep sequencing of any complex genomic region
of interest and may be a straightforward approach for
detecting causal variants in common diseases and
contribute to the understanding of their pathogenesis.
However, the costs and efforts for library preparation and
enrichment of larger sample sets necessary to discover
enough rare variants to build pathway models for
common disease are significant. Therefore, we explored
a cost-reducing strategy by pooling of samples at the
level of genomic DNA with subsequent library prepara-
tion, genomic enrichment, and sequencing of patient
pools rather than individual samples. The identified
candidate variants are subsequently confirmed by capillary
sequencing of individual samples from a pool.
The strategy for the pooled DNA sequencing and its
analysis differs from standard non-pooled NGS strategies.
Accurate equimolar pooling of each genomic DNA is
important for equal distribution of reads and the number of
pooled samples should be balanced for successful variant
detection. In this study, we focused on the discovery of rare
variants in the replicable AAA genome-wide association
study (GWAS) locus on 9p21 and 42 AAA candidate
genes. We used a group of 100 well-characterized Dutch
AAA patients that were divided into five pools of 20
individual genomic DNA samples. To detect a single
heterozygote variant in the presence of 40 chromosomes,
the variant calling thresholds for the non-reference allele
percentage (NRA%) needed to be lowered to ~2.5%. We
found that at this cut-off level, the majority of detected rare
variants were false positives, indicating that lower pooling
depths or individual indexing of samples is the preferred
strategy.
Material and Methods
Patient Selection
The AAA samples in this study (n=100) were collected
during a recruitment effort in the years 2007–2009 by the
Department of Medical Genetics, University Medical
Center Utrecht, The Netherlands from eight large AAA-
treating centers in the Netherlands. This sample collection
was previously used for the discovery of common variants
associated with AAA [10, 11, 13, 15]. Blood for genomic
DNA isolation was obtained mainly when individuals
visited their vascular surgeon in the polyclinic or, in rare
cases, during hospital admission for elective or emergency
AAA surgery. An AAA was diagnosed if the diameter of
the infrarenal aorta was ≥30 mm. The sample set comprised
Fig. 1 Schematic overview of
the pathway model for common
diseases. The pathway model
of common diseases assumes
that disease of a specific organ
or tissue can be caused by
impairment of any pathway
influencing physiological
function of the organ or tissue.
Each pathway contains several
genes and any point mutation or
structural variation in relevant
genes can contribute to the onset
of the disease. Additionally,
not only genetic but also
intergenic mutations having a
trans-effect on protein function
should be considered. In
addition to genetic factors,
also environmental factors are
expected to have a significant
effect
272 J. of Cardiovasc. Trans. Res. (2011) 4:271–28084% males, with a mean AAA diameter of 58.4 mm, 70%
had received surgery, of which 2% was emergency. Of the
patients, 59% reported a history of smoking, 29% had a
familial history of AAA, 65% were diagnosed with
hypertension, and 58% with other cardiovascular disease.
The average age of patients was 76 years. Patients were
divided per five pools of 20 according to sharing or absence
of at least one major risk factor for AAA formation as
follows: (1) never smoked, (2) family history of AAA, (3)
other reported cardiovascular disease, (4) hypertension, and
(5) mixed group (Table 1).
Array Design
The list of genomic sequences for array design was divided
into four groups: (1) the whole 9p21.3 locus detected by
GWAS (the only replicable locus at the time of our array
design), including full genes and intergenic regions, (2)
coding sequences of pathway candidates from genes in the
9p21.3 locus, (3) coding sequences of genes from the TGF-
beta pathway, and (4) coding sequences of additional
candidate genes based on current literature (Table 2). The
probe selection strategy was set using our previously
described criteria [19]. The small target size allowed for a
dense design where a capture probe starts on average every
other base. For every 2-bp window, a single 60 bp long
probe with the lowest penalty score was selected, resulting
in average 30× probe coverage for both the negative and
positive strand. To exclude potentially repetitive elements
from the design, all probes were compared to the reference
genome GRCh37/hg19 using BLAST and those returning
more than one additional hit (as defined by >60% matching
region) were discarded from the design. The final array
design consisted of 425,892 uniquely mapping probes
resulting into a design footprint of 498,658 bp. We define
as “Request” the set of genomic positions of interest and
“Design” as the genomic positions, which were covered by
enrichment probes. Due to repetitive elements and low
complexity in the intergenic and intronic regions of the
9p21.3 locus, 57.4% of all requested genomic positions and
99.6% of the requested protein-coding regions were
covered by capture probes. Probes were synthesized on
custom 1 Mb array (Agilent Technologies, CA, USA, five
copies) with randomized positioning.
Library Preparation
Genomic DNA concentration of each sample was deter-
mined using the Quant-iT™ PicoGreen ® dsDNA method
(Invitrogen). After measurements, 200 ng of each sample
was used for subsequent equimolar pooling (five pools of
20 patients) at the level of genomic DNA and 4 μg of each
pool was used as input material for preparation of five
fragment libraries and targeted genomic enrichment on
array for the SOLiD NGS platform as described previously
[19]. In brief, each genomic DNA pool was fragmented
using Covaris™ S2 System (Applied Biosystems) to 100–
150 bp short fragments. After fragmentation, fragments
were blunt-ended and phosphorylated at the 5′ end using
End-It™ DNA End-Repair Kit (EpiCenter) for 30 min. at
RT. Samples were then purified with the Agencourt
AMPure XP system (Beckman Coulter Genomics) followed
by ligation of double-stranded truncated versions of
adaptors complementary to the SOLID next generation
sequencing platform. Adaptors were prepared by hybridiza-
tion of complementary HPLC-purified oligonucleotides.
Ligation was performed using Quick Ligation Kit (New
England BioLabs) for 10 min. at RT. After purification
with the AMPure system, nick translation on non-
phosphorylated and non-ligated 3′-ends and amplification
in single polymerase chain reaction (PCR) reaction was
done for each library separately using primer 1 comple-
mentary to adaptor 1 (5′-CTA TGG GCA GTC GGT
GAT-3′) and primer 2 complementary to adaptor 2 (5′-
GCT GTA CGG CCA AGG CG-3) at 72°C for 5 min for
nick translation and followed by 95°C for 5 min, five
cycles: 95°C for 15 s, 54°C for 15 s, 70°C for 1 min,
70°C for 4 min and 4°C hold. Intensity of library bands
was checked on 2% agarose gel (Lonza FlashGel
System). PCR products were purified with AMPure
system to remove adaptor dimmers and heterodimmers.
Amplified library fragments ranging 120–200 bp were
Table 1 Clinical information about the AAA patient set
Patient
pool
Diameter of aorta
[mm]
a
Gender
f/m
Operated Rupture Ever
smoked
Hypertension Cardiovascular
disease
Familial
AAA
1 59.9 5/15 16 0 0 13 10 8
2 61.2 4/16 14 0 14 14 8 20
3 60.8 0/20 15 0 20 8 20 0
4 51.4 2/18 11 0 12 20 11 1
5 60.6 2/18 14 2 13 10 9 0
aDiameter of infrarenal aorta. The cut-off for diagnosis of AAA was set at 30 mm.
J. of Cardiovasc. Trans. Res. (2011) 4:271–280 273Table 2 Overview of the locus and genes included into array design
Gene name Gene description Ensemble gene
name
GRCh37 location
1. 9p21.3 locus Chromosome 9: 21,750,000–22,400,000
Containing genes
CDKN2A Cyclin-dependent kinase inhibitor 2A
(melanoma, p16, inhibits CDK4)
ENSG00000147889 Chromosome 9: 21,967,752–21,995,300
CDKN2B Cyclin-dependent kinase inhibitor 2B
(p15, inhibits CDK4)
ENSG00000147883 Chromosome 9: 22,002,902–22,009,280
CDKN2BAS CDKN2B antisense RNA
(non-protein coding)
ENSG00000240498 Chromosome 9: 21,994,790–22,121,096
2. CDK pathway
CDK1 Cyclin-dependent kinase 1 ENSG00000170312 Chromosome 10: 62,538,101–62,554,610
CDK2 Cyclin-dependent kinase 2 ENSG00000123374 Chromosome 12: 56,360,556–56,366,565
CDK3 Cyclin-dependent kinase 3 ENSG00000108504 Chromosome 17: 73,975,312–74,002,080
CDK4 Cyclin-dependent kinase 4 ENSG00000135446 Chromosome 12: 58,142,005–58,146,164
CDK5 Cyclin-dependent kinase 5 ENSG00000164885 Chromosome 7: 150,750,899–150,754,996
CDK6 Cyclin-dependent kinase 6 ENSG00000105810 Chromosome 7: 92,234,239–92,465,941
CDK7 Cyclin-dependent kinase 7 ENSG00000134058 Chromosome 5: 68,530,622–68,573,256
CDKN2C Cyclin-dependent kinase inhibitor 2C ENSG00000123080 Chromosome 1: 51,426,417–51,440,309
CDKN2D Cyclin-dependent kinase inhibitor 2D ENSG00000129355 Chromosome 19: 10,677,139–10,679,655
TP53 Tumor protein p53 ENSG00000141510 Chromosome 17: 7,565,257–7,590,863
MDM1 Mdm1 nuclear protein homolog (mouse) ENSG00000111554 Chromosome 12: 68,688,346–68,726,161
MDM2 Mdm2 p53 binding protein homolog (mouse) ENSG00000135679 Chromosome 12: 69,201,980–69,234,214
3. TGFbeta pathway
TGFB1 Transforming growth factor, beta 1 ENSG00000105329 Chromosome 19: 41,836,651–41,859,816
TGFB2 Transforming growth factor, beta 2 ENSG00000092969 Chromosome 1: 218,519,391–218,617,959
TGFB3 Transforming growth factor, beta 3 ENSG00000119699 Chromosome 14: 76,424,442–76,448,092
FBN1 Fibrillin 1 ENSG00000166147 Chromosome 15: 48,700,505–48,937,918
LTBP1 Latent transforming growth factor beta
binding protein 1
ENSG00000049323 Chromosome 2: 33,359,706–33,624,576
THBS1 Thrombospondin 1 ENSG00000137801 Chromosome 15: 39,873,280–39,889,665
DCN Decorin ENSG00000011465 Chromosome 12: 91,539,036–91,576,806
ACVRL1 Activin A receptor type II-like 1 ENSG00000139567 Chromosome 12: 52,301,202–52,317,145
ACVR1B Activin A receptor, type IB ENSG00000135503 Chromosome 12: 52,345,486–52,390,857
TGFBR1 Transforming growth factor, beta receptor I ENSG00000106799 Chromosome 9: 101,867,412–101,916,474
TGFBR2 Transforming growth factor, beta receptor II ENSG00000163513 Chromosome 3: 30,647,994–30,735,634
TGFBR3 Transforming growth factor, beta receptor III ENSG00000069702 Chromosome 1: 92,145,900–92,371,559
ENG Endoglin ENSG00000106991 Chromosome 9: 130,577,291–130,617,047
SMAD2 SMAD family member 2 ENSG00000175387 Chromosome 18: 45,359,466–45,456,926
SMAD3 SMAD family member 3 ENSG00000166949 Chromosome 15: 67,358,195–67,487,532
SMAD4 SMAD family member 4 ENSG00000141646 Chromosome 18: 48,556,583–48,611,415
SMAD6 SMAD family member 6 ENSG00000137834 Chromosome 15: 66,994,634–67,074,323
SMAD7 SMAD family member 7 ENSG00000101665 Chromosome 18: 46,446,224–46,477,081
4. Other candidate genes
ELN Elastin ENSG00000049540 Chromosome 7: 73,442,119–73,484,237
ACTA2 Actin, alpha 2, smooth muscle, aorta ENSG00000107796 Chromosome 10: 90,694,831–90,751,147
MYH11 Myosin, heavy chain 11, smooth muscle ENSG00000133392 Chromosome 16: 15,796,992–15,950,890
ACE Angiotensin I converting enzyme
(peptidyl-dipeptidase A) 1
ENSG00000159640 Chromosome 17: 61,554,432–61,599,209
NOS Nitric oxide synthase 3 (endothelial cell) ENSG00000164867 Chromosome 7: 150,688,083–150,711,676
MMP2 Matrix metallopeptidase 2 (gelatinase A,
72 kDa gelatinase, 72 kDa type IV collagenase)
ENSG00000087245 Chromosome 16: 55,512,883–55,540,603
274 J. of Cardiovasc. Trans. Res. (2011) 4:271–280size selected on 4% agarose gel and gel slices were
purified using QIAquick Gel Extraction Kit (Qiagen).
After size selection, additional 12 PCR cycles using
aforementioned PCR program were performed to obtain
enough material for array enrichment.
Array-based Targeted Genomic Enrichment
For array-based targeted genomic enrichment of DNA
libraries, we used an optimized protocol using enrichment
arrays and elution settings from Agilent Technologies and
NimbleGen hybridization and washing buffers and con-
ditions [19, 20]. Of each library, 2,500 ng was mixed with
5× weight excess of human Cot-1 DNA (Invitrogen) for
nonspecific hybridization, and concentrated using a speed-
vac to a final volume of 12.3 μl. DNA was mixed with
NimbleGen Hybridization Kit and denatured at 95°C for
5 min. After denaturing, each pool library was hybridized
on a separate enrichment array for 65 h at 42°C on a four-
bay MAUI hybridization station using an active mixing
MAUI AO chamber (BioMicro Systems). After hybridiza-
tion, arrays were washed using the Nimblege Wash
Buffer Kit (Roche) according to the user’sg u i d ef o r
aCGH hybridization. The temperature of Wash buffer I
for library 2 was 42°C instead of room temperature.
Elution was performed using 800 ml of elution buffer
(10 mM Tris pH 8.0) in a DNA Microarray Hybridization
Chamber–SureHyb(Agilent)at95°Cfor30min.After30min,
the chamber was quickly disassembled and elution buffer
was collected into a separate 1.5 ml tube. Eluted ssDNA
libraries were concentrated in a speedvac to a final volume of
30 μl. Each eluate has been used for post-hybridization PCR
for introducing the full length SOLiD adaptor P1 and
multiplex adaptor P2 with a barcode sequence (BC7, 9, 10,
11, 12). Primer 3 (5′-CCA CTA CGC CTC CGC TTT CCT
CTC-3′)a n dP r i m e r4( 5 ′-CTG CCC CGG GTT CCT CAT
TCT CTN NNN NNN NNN CTG CTG TAC GGC CAA
GGC G-3′, where N represents unique sequence for each
barcode) were used for 12 cycles in the above-mentioned
PCR program. PCR products were purified with the
MinElute PCR Purification Kit (Qiagen).
Sequencing, Variant Detection and Analysis
SOLiD sequencing was performed according to the SOLiD
v3+ manual. Before emulsion PCR, all five pool libraries
were quantified with the Quant-iT™ dsDNA HS Assay Kit
(Invitrogen) to obtain equal amount of reads per pool. All
five enriched pools were deposited on one sequencing slide
and sequenced using SOLiD v3+ system to produce enough
50 bp reads to obtain sufficient coverage for a single allele.
Color space reads were mapped against the GRCh37/hg19
reference genome for Human with BWA software [21].
Single nucleotide variants (SNVs) and small indels (≤7nt)
were called by our custom analysis pipeline as described
before [20] (all scripts available upon request). All common
and rare polymorphisms present in Ensembl59 were tagged
as known; other variants were considered to be novel. The
criteria for variant detection were set as follows: minimally
three independent reads on the positive and three on the
negative strand, cut-off for coverage was set to 500 reads
and cut-off for NRA% was set to 3%. To allow detection of
one variant allele in a pool of 40 alleles the cut-off for
NRA% should be lowered to theoretical 2.5%. However, this
increased the number of detected variants exponentially and
we empirically determined that 3% NRA gives a reasonable
number of novel candidate variants. We included also a
clonality filter that keeps maximally five clonal reads with the
same start site and removes reads above this level. This
clonality filter was already used in our previous reports
[19, 20]. For each variant, location in genomic sequence,
amino acid change, effect on the protein function, and
conservation score were collected and subsequently used for
prioritization for candidate variants. Confirmation of selected
candidate mutations was performed by capillary sequencing
and primer information is available under request.
Table 2 (continued)
Gene name Gene description Ensemble gene
name
GRCh37 location
MMP9 Matrix metallopeptidase 9 (gelatinase B,
92 kDa gelatinase, 92 kDa type IV collagenase)
ENSG00000100985 Chromosome 20: 44,637,547–44,645,200
TIMP1 TIMPmetallopeptidase inhibitor 1 ENSG00000102265 Chromosome X: 47,441,712–47,446,188
MTHFR Methylenetetrahydrofolate reductase (NAD(P)H) ENSG00000177000 Chromosome 1: 11,845,780–11,866,977
ABCA1 ATP-binding cassette, sub-family A (ABC1),
member 1
ENSG00000165029 Chromosome 9: 107,543,283–107,690,518
ABCB5 ATP-binding cassette, sub-family B
(MDR/TAP), member 5
ENSG00000004846 Chromosome 7: 20,654,830–20,816,658
ABCC6 ATP-binding cassette, sub-family C
(CFTR/MRP), member 6
ENSG00000091262 Chromosome 16: 16,243,422–16,317,328
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Sequencing of the five pools in a single slide SOLiD run
resulted in 270,024,207 raw 50-mer reads (Fig. 2a) with
even coverage distribution across the designed region:
99.9% of the target design was covered by at least one
read, 99.3±0.3% covered by at least 20 reads and 91.3±3%
covered by at least 500 reads (Fig. 2c). From all produced
raw sequencing reads (270,024,207), 72.2±0.8% mapped
to the GRCh37/hg19 genome build for human and 48.6±
3.3% of all mapped reads overlapped with the enrichment
design (Fig. 2b). The second percentage is often referred to
as enrichment efficiency and correlates with our previous
observations that design sizes smaller than 1 Mb (in our
case ~0.5 Mb) have lower enrichment efficiency in
comparison with designs larger than 1 Mb (up to 60–70%).
For each patient pool, we obtained a mean bp coverage of
2,514±481readsandmedianbpcoverageof2,158±497reads
and the small difference between these two values (14.6±
3.2%) can be used as indirect measure of even distribution
(Fig. 2d). Evenness of coverage defined by an evenness score
is similar in all five pools (72.4±0.2) and falls into the normal
range of 70–75% as described before [19]( F i g .2e). More
than 99% of all bp position from the designed regions was
covered by at least 10% of mean coverage (Fig. 3).
Using pre-defined settings with an allele cut-off >3%,
we detected 2,236.8±166.1 variants per pool. A detailed
overview of the number of variants for each patient pool
can be found in Table 3. The number of coding variants
found per gene correlates with the size of its coding
sequence as shown in Fig. 2f and suggests a random
distribution of detected variants. Altogether, we detected
681 coding variants of which 608 were novel and 73 were
present in dbSNP. This is deviating from previous obser-
Fig. 2 Sequencing, mapping and enrichment statistics. The total
number of reads produced, number of reads mapping to the reference
genome and number of reads overlapping with the enrichment design
(a), the percentage of mappability and enrichment efficiency (b),
design footprint covered by ≥1 read, by ≥20 reads, and by ≥500 reads
(c), mean and median bp coverage (d), and evenness score (e) show
similar pattern for all five patient pools indicating the robustness of the
method. The number of novel variants detected in all five patient
pools correlates with the size of the coding sequence of genes (f)
indicating a random distribution of detected variants. It is not possible
to statistically test for enrichment of variants in genes since we did not
include control genes or control samples (full line trend line, dashed
line mean value line, R
2 trend line equation)
Fig. 3 Distribution of sequencing coverage. The plot indicates the
percentage of bases in the design that is covered by the depth of
coverage normalized for the average coverage. Example: on average
99% of all bp is covered by at least 10-percentile of mean coverage
(251.4±48.1 per pool) and approximately 40% of all bp reached the
mean coverage (2,514±481 per pool)
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experiments usually represent 10–15% of all detected
variants. The high percentage of potential novel variants
detected in our study (89%) could be due to the very low
threshold that had to be set for detection of single variant
alleles in a pool of 40, complicating the distinction of true
variants from noise. As expected, this led to a skewed
NRA distribution in AAA pools, which is significantly
deviating from the typical pattern observed in non-pooled
experiments where a peak for heterozygous mutations at
30–50% NRA and homozygous mutations close to
100% NRA can be detected (Fig. 4). Usually, the region
below 20% NRA contains the majority of false positive
variants [19, 20], although this depends strongly on the
depth of coverage. Within the range of 3–100%NRA, 77%
of all detected coding variants had an allele frequency in
one of the pools of ≤10% while the allele frequency for
novel variants was ≤25%.
Prioritization of candidate variants requires a substantial
effort due to the high number of mutations discovered per
pool and the fact that majority of them was novel and
below 20% NRA. We decided to select 20 candidate novel
coding variants with significant effect on protein and
conservation score with NRA% ranging from 3% to 25%
(Table 4). We performed capillary sequencing on each
patient from a pool separately but failed to confirm any of
the predicted variants, suggesting that the majority of
candidate novel detected variants are false positives. This
is indicative of a relatively high error rate in the sequencing
process. Due to the high number of variants detected and
Type of mutation Patient pool
12345
Non-synonymous coding
a 229 193 265 239 236
Stop-gained 5 9 7 7 5
Stop-lost 1 1 0 0 0
Essential splice site 2 3 2 4 5
Splice site 9 11 7 11 14
Synonymous coding 61 56 61 57 64
5'UTR 48 31 47 60 54
3'UTR 191 185 201 201 222
Intronic 79 80 91 87 89
Downstream 222 228 251 276 255
Upstream 285 273 329 319 299
Intergenic 578 582 649 739 626
Within non-coding gene 357 352 380 403 406
Small InDels 28 31 29 30 27
All mutations 2,095 2,035 2,319 2,433 2,302
Table 3 List of mutations
detected in five pools
aEnsemble predicted variation
consequences
Fig. 4 Non-reference allele percentage distribution of detected
variants in AAA patient pools. Non-reference allele (NRA) percentage
distribution of detected variants in AAA pools is significantly
deviating from the commonly observed pattern in non-pooled experi-
ments with a clear peak for heterozygous mutations at 30–50% NRA
and homozygous mutations close to 100% NRA. Dashed lines are
indicative of a distribution of NRA% of novel and known variants
from an exome sequencing of a healthy individual
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unknown until capillary sequencing confirmation, we did
not perform a classical systematic verification of the false
negative discovery rate. On the other hand, we were able to
spot common variants previously detected in GWAS studies
and candidate genes association studies using the same
sample collection [10, 11, 13, 15] (data not shown).
Discussion
Here, we present our results with a genomic DNA pooling
strategy for rare variant discovery on an NGS platform.
This pilot experiment was designed to find an efficient
method for detection of rare genetic variants in genomic
regions of interest in large sample groups. Our primary aim
was to test the hypothesis of the “pathway model” in our
AAA sample collection. We planned to confirm the
principle on a group of 5×20 patients and test detected
variants in an additional collection of 1,400 patient samples
and suitable control group. However, though we succeeded
in obtaining a high average tiling density of our probe
design, even coverage distribution and high mean bp
coverage, this approach failed because low frequency
alleles in the pool (e.g., a heterozygous variant in one
sample in a pool of 20 samples) could not be reliably
distinguished from noise. While decreasing the cut-off for
NRA% to 2.5% increased the number of detected variants
Table 4 List of novel variants selected for capillary sequencing confirmation
Chr. Position
a Allele
change
Amino acid
change
Amino acid
position
b
Gene
name
Gerp1
c Gerp2
d Mutation effect Patient pool NRA%
12 3 45
1 218520046 G/A MET/ILE 1/443 TGFB2 2.82 1.165 Non-synonymous
coding
12 13 11 11
e 8
2 33477855 G/C CYS/SER 378/1397 LTBP1 2.82 2.171 Non-synonymous
coding
81 6 1 3 1 5
e -
3 30732960 C/A PRO/THR 550/593 TGFBR2 2.9 2.094 Non-synonymous
coding
7
e ––– –
3 148459750 A/T LYS/stop 310/360 AGTR1 No score No score Stop-gained –– – 3
e –
5 68555715 A/C LYS/THR 160/347 CDK7 2.82 1.788 Non-synonymous
coding
– 14 – 15
e –
7 150698940 A/G THR/ALA 512/1204 NOS3 2.32 1.41 Non-synonymous
coding
10
e 5 – 75
9 101891203 T/G PHE/CYS 55/427 TGFBR1 2.9 1.796 Non-synonymous
coding
55 8 6
e 5
9 101891219 G/C GLU/ASP 60/427 TGFBR1 1.96 1.601 Non-synonymous
coding
–– 6
e 4 –
9 101894941 C/T SER/LEU 165/504 TGFBR1 2.9 1.614 Non-synonymous
coding
5 – 4
e – 3
12 52309230 A/T LYS/stop 332/504 ACVRL1 1.95 1.444 Stop-gained – 65
e – 3
12 68707507 T/C LYS/ARG 509/715 MDM1 −1.15 0.841 Non-synonymous
coding
18
e 19 – 15 –
15 48787411 A/T CYS/stop 862/2872 FBN1 1.66 1.497 Stop-gained 3 3 4 3
e –
15 48807601 A/T LEU/HIS 484/2872 FBN1 2.9 1.508 Non-synonymous
coding
– 33
e – 3
15 48888508 G/C TYR/stop 170/2872 FBN1 1.11 1.114 Stop gained – 34
e ––
15 48888520 A/T CYS/stop 166/2872 FBN1 −0.67 0.961 Stop-gained 4 4 7
e – 8
15 67073635 A/G ASP/GLY 157/236 SMAD6 1.87 1.144 Non-synonymous
coding
5
e – 43 6
16 15841741 C/G CYS/SER 754/1946 MYH11 2.82 2.118 Non-synonymous
coding
68 1 1 1 3
e 11
16 15932031 G/A GLN/stop 27/1946 MYH11 2.82 2.017 Stop-gained –– – 3
e –
16 16282720 A/G PHE/LEU 583/1504 ABCC6 2.82 1.713 Non-synonymous
coding
5
e 6 – 76
16 55530885 T/C LEU/PRO 457/611 MMP2 2.9 1.361 Non-synonymous
coding
44 5 5
e 6
aEnsembl59 coordinate
bFirst number indicates the position of mutation, second total number of amino acids in a transcript
cEnsembl Genomic Evolutionary Rate Profiling (GERP) score
dEnsembl predicted variation consequences
ePool used for cappilary sequencing confirmation
278 J. of Cardiovasc. Trans. Res. (2011) 4:271–280exponentially, we decided to first verify candidates under
more stringent conditions reflecting two or more alleles in
the pool (3% NRA). However, even under stringent
conditions, verification of our biological candidates was
unsuccessful.
Genomic DNA pooling strategies have a clear potential
for discovery of variants that are common, as reported in
several GWAS studies [22–24]. Bansal et al. could
indentify 80–85% of low frequency single-nucleotide
polymorphisms when using pools of 25 samples compared
to results obtained with a non-pooled approach [25]. Recent
NGS studies have shown that pooling of samples at the
level of genomic DNA up to 20-fold and subsequent
amplification of coding exons of candidate genes by
conventional PCR does allow for the detection of novel
variants in rare diseases [26–28]. However, these experi-
ments did not use targeted genomic NGS enrichment as
described in our study. On the other hand, the advantage of
NGS targeted genomic enrichment in comparison to the
conventional PCR assays is the size of genomic regions that
can be assessed in a single experiment (one enrichment
allows for up to 50 Mb of genomic target sequence). While
diagnostic labs have successfully developed a wide range of
amplicon assays for rare diseases, it could be argued that
for research purposes of common diseases, it would be
relatively laborious to develop such assays as compared to
a universal NGS enrichment-based approach. The afore-
mentioned studies also included control samples for
discarding variants; we planned to perform the biological
filtering by capillary sequencing of detected variants
afterwards.
The reason for failure of our approach is that the single
heterozygote allele frequency is close to the sequencing
noise level in a pool of 20 samples. This noise could
arise during any step of library preparation, enrichment,
sequencing, or mapping. We do not have data supporting
or excluding the possibility that any other NGS platform
would perform differently from the SOLiD platform.
There are no indications that specific errors are introduced
due to biases in SOLiD sequencing, making it impossible to
systematically exclude specific errors from the lists of
detected variants by biological filtering. Furthermore, the
library preparation and enrichment method we used was
d e v e l o p e da sa ni m p r o v e dm e t h o df o ra r r a ye n r i c h m e n t
on the SOLiD sequencing platform, which performed
better than the commercially available methods [19]. It
could be possible that pre and post-enrichment PCR
cycles may contribute to higher rates of noise as
compared to for example whole genome sequencing.
These levels are not problematic for non-pooled
approaches [19, 20] but may become a problem for pooled
approaches as described here. We minimized the number
of PCR cycles during library preparation and enrichment
to five cycles during library preparation, 12 cycles prior to
enrichment, and 12 cycles after enrichment.
Possible solutions for the improvement of this pooling
approach would be decreasing the number of pooled
samples or decreasing the noise introduced by library
preparation, enrichment, sequencing, and mapping. With a
decreasing number of pooled samples, the cut-off of NRA%
for the detection of a single allele can be increased and the
difference between noise and a single heterozygote call in
the pool would be much larger and the call more
distinguishable. However, this would require the generation
of more pools, which would not be attractive for the
analysis of large cohorts. We performed the experiment
described here before we introduced an alternative multi-
plexed enrichment approach with pre-barcoded samples
[20]. Using multiplexed enrichment sequencing results can
be split per sample, resulting in efficient variant detection
with novel variant confirmation rates of 50–90% (in
contrast to 0% described in the study described here)
without biases for allele frequency and with no adverse
effects on the NRA% distribution in comparison to the non-
pooled experiments. Although multiplexed enrichment
gives rise to an increased burden of library preparation,
this step can easily be automated and therefore, we
recommend using barcoded multiplexed enrichment rather
that non-indexed genomic DNA pooling for rare variant
detection in common diseases on current versions of next-
generation sequencing platforms.
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